Trial Profile
Safety and Efficacy of Eltrombopag in Patients Undergoing Cord Blood or Haploidentical Bone Marrow Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Bone marrow transplant rejection; Cord blood stem cell transplant rejection
- Focus Therapeutic Use
- 14 Jun 2023 Status changed from active, no longer recruiting to completed.
- 02 Feb 2023 Planned End Date changed from 31 Jan 2023 to 30 Jun 2023.
- 02 Feb 2023 Planned primary completion date changed from 31 Jan 2023 to 30 Jun 2023.